European Medicines Agency: Medicines highlights : EMA has agreed four changes to human medicines for the treatment of cancer in January 2011.
Tuesday 15 March 2011
Positive CHMP recommendations* on new medicines - Jevtana (cabazitaxel) - Treatment of prostate cancer
Positive CHMP recommendations* on new medicines - Halaven (eribulin) - Treatment of breast cancer
New marketing authorisations - Potactasol (topotecan) - Treatment of metastatic cancer of the ovary and small cell lung cancer
Withdrawal of marketing authorisation applications - Tekinex (omacetaxine mepesuccinate) - Intended for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (CML)
More details can be found at:
>> http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/q_and_a/q_and_a_detail_000109.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac05802d81e5
European Oncology Nursing SocietyAvenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu